AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...

Additionally, EvolveImmune will receive option fees and milestone payments of up to $1.4bn, and tiered royalties on future ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell resistance to current immunotherapies, has signed a collaboration and ...

This morning, pharma major AbbVie and fellow USA-based EvolveImmune Therapeutics announced the signing of a collaboration and ...

Evolveimmune Therapeutics Inc. has secured its fourth big pharma investor and its first pharma development partnership in a deal with Abbvie Inc. The multitarget development deal with North ...

AbbVie (ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current ...

Biotherapeutic firm EvolveImmune Therapeutics gets $65 million upfront and potentially $1.4 billion more if drugmaker AbbVie licenses its T-cell therapy.

AbbVie has inked a deal to work with privately held immuno-oncology company EvolveImmune Therapeutics, to develop therapeutic antibodies for cancer.

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop next-generation cancer biotherapeutics. The partnership will focus on creating ...